CLICK TO ORDER THE FIGHT
Chicago, Illinois (July 12 2011) – The Main Event on July 15th 2011 is none other than welterweight title contender Lanardo “The Pain Server” Tyner (24-4 15KO’s) will be facing former WBA light welterweight champion “Vicious” Vivian Harris (29-6 19KO’s) for the USBO welterweight championship.
Tyner born and raised in Detroit, Michigan is looking for bigger fights after this scheduled bout with Harris. Tyner now managed by Wasfi Tolaymat and trained by Floyd Mayweather Sr knows that a victory against Vivian Harris can launch him into bigger paydays.
“I am happy to be back into Chicago, I love the fans of the Windy City. Chicago is a city with die hard sports fans and I am honored for them to welcome me in as an adopted son of the city” said Tyner.
Tyner who was last seen in Chicago on March 25th 2011 fighting fast rising prospect Adrian Granados to a draw is looking to showcase what he calls “The New and Improved” Lanardo Tyner. “I have been training hard, away from my family for two months I am ready to leave everything in the ring on July 15th.
The fight is a must win for Harris who was born in Georgetown, Guyana and now resides in Brooklyn, New York. Harris who recently been on the downside is looking to bounce back after his recent loss to current WBC welterweight champion “Vicious” Victor Ortiz. Harris knows a loss against Tyner can be more than just a minor set back; it can also mark an end to a great career.
The media is looking closely at this fight for a number of reasons as well; winner goes on to earn an IBO world title shot. Jason Ford of fight news was quoted earlier this week predicting this match to be the “Fight Of The Night”.
The Co-Main event will feature current WBA Pan African & ABU light welterweight champion “Tornado” Albert Mensah (23-3-1 10KO’s) facing Canadian star “Gorgeous” Andre Gorges (11-1 6KO’s) for the vacant IBF International Light Welterweight championship.
The Undercard will feature the return of Chicago favorites such as “Fearless” Fernando Hernandez, Antonio “Aztec God Of War” Canas, Eric “Loco” Estrada, Adrian Granados, Sergio Montes De Oca, Donatas Bondoravas and MMA title contender Boban Simic who will be making his long awaited pro boxing debut.
Tickets for CHICAGO FIGHT NIGHT II, starting at $30 can be purchased in advance at Shop & Save, Cermak Produce, or Chicago Fight Club (http://www.chicagofightclubs.com) 708-333-3303 and Will County Boxing Gym (http://www.willcountyboxing.com) 815-661-0247.
Doors on the evening of the event will open at 7pm with the first bell at 8pm. The Club is located at 7600 S. Cicero Ave. Burbank, IL. For further information, please visit their website at (http://www.theclubchicago.com). The Club is serving alcohol at all boxing events.
Reduced-dose therapy is promising in Hodgkin’s disease, study finds.(Hematology)
Internal Medicine News February 1, 2006 | Jancin, Bruce DENVER — Dosing of combined chemo- and radiotherapy can be reduced to levels well below those considered standard with no significant loss of effectiveness in patients with early-stage Hodgkin’s disease, according to the interim analysis of a large, German, randomized trial. site hodgkin s disease
Further follow-up in the study is predicted to find that the reduction in the radiation therapy dose to 20 gray (Gy) will almost certainly pay off in the form of far fewer secondary cancers than with the standard 30 Gy, Dr. Rolf-Peter Mueller said at the annual meeting of the American Society for Therapeutic Radiology and Oncology.
Short- and mid-term toxicities were less in patients who got lower-dose therapy, but not dramatically so, prompting investigators to launch new ongoing studies involving still-greater dose reductions in treating early Hodgkin’s lymphoma, added Dr. Mueller, professor and chair of radiation oncology at the University of Cologne, Germany.
Sequential treatment involving multiple cycles of chemotherapy followed by a course of radiotherapy is today considered the standard for early Hodgkin’s disease. Dr. Mueller presented an interim analysis of the German Hodgkin Study Group Trial HD-10, in which 1,370 patients with early-stage Hodgkin’s lymphoma with no unfavorable prognosis risk factors were randomized to one of four treatment arms in a 2 x 2 factorial design.
The standard therapy arm consisted of four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy followed by radiation therapy at 30 Gy limited to the involved field. The three dose-reduction regimens were four cycles of chemotherapy followed by 20 Gy of radiotherapy, two cycles of chemotherapy and 30 Gy of radiotherapy, and two cycles of chemotherapy and 20 Gy of radiotherapy.
An earlier trial by the German Hodgkin Study Group established that involved-field radiotherapy was as effective as extended-field while reducing by half the body area receiving radiation. see here hodgkin s disease
With HD-10 results available to date for 1,107 patients at a median 41 months of follow-up, 4-year overall survival was similar in all four study arms, at about 97%. Freedom from treatment failure didn’t differ significantly among the four groups, with a rate of roughly 94%. The relapse rate was 3.25%. Since most relapses of Hodgkin’s disease occur within the first 2 years following treatment, the interim and final study results are likely to be quite similar, he explained.
The most common World Health Organization grade 3/4 toxicity during chemotherapy was leukopenia, with an incidence of 22% with four-cycle therapy and 15% with two-cycle therapy. Infection was also significantly more common in patients who received four cycles of chemotherapy.
The incidence of WHO grade 3/4 toxicities during radiotherapy was 3%, mostly dysphagia and mucositis.
